A Bayesian Approach to Improved Estimation of Causal Effect Predictiveness for a Principal Surrogate Endpoint

Biometrics

Volumn 68, Issue 3, 2012, Pages 922-932

  Zigler, Corwin M ^a   Belin, Thomas R ^b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Biomarker; Causal effect predictiveness; Principal stratification; Surrogate endpoint

Indexed keywords

BAYESIAN NETWORKS;

BAYESIAN APPROACHES; BAYESIAN METHODS; CAUSAL EFFECT PREDICTIVENESS; CAUSAL RELATIONSHIPS; CLINICAL TRIAL; OBSERVED QUANTITY; ON POTENTIALS; POTENTIAL OUTCOMES; PRINCIPAL STRATIFICATION; SURROGATE ENDPOINT;

VACCINES;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BAYESIAN ANALYSIS; BIOMARKER; HUMAN IMMUNODEFICIENCY VIRUS; LITERATURE REVIEW; PERFORMANCE ASSESSMENT; PRINCIPAL COMPONENT ANALYSIS; SURROGATE METHOD;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84866768216     PISSN: 0006341X     EISSN: 15410420     Source Type: Journal    
DOI: 10.1111/j.1541-0420.2011.01736.x     Document Type: Article

References (20)

1. Bartolucci, F. and Grilli, L. (2011). Modeling partial compliance through copulas in a principal stratification framework. Journal of the American Statistical Association 106, 469-479.
2. Chen, H., Geng, Z., and Jia, J. (2007). Criteria for surrogate end points. Journal Of The Royal Statistical Society Series B 69, 919-932.
3. Cochran, W. G. (1957). Analysis of covariance: Its nature and uses. Biometrics 13, 261-281.
4. Follmann, D. (2006). Augmented designs to assess immune response in vaccine trials. Biometrics 62, 1161-1169.
5. Frangakis, C. E. and Rubin, D. B. (2002). Principal stratification in causal inference. Biometrics 58, 21-29.
6. Gelfand, A. E. and Smith, A. F. M. (1990). Sampling-based approaches to calculating marginal densities. Journal of the American Statistical Association 85, 398-409.
7. Gelman, A. and Rubin, D. B. (1992). Inference from iterative simulation using multiple sequences. Statistical Science 7, 457-472.
8. Gilbert, P. B. and Hudgens, M. G. (2008). Evaluating candidate principal surrogate endpoints. Biometrics 64, 1146-1154.
9. Gilbert, P. B., Qin, L., and Self, S. G. (2008). Evaluating a surrogate endpoint at three levels, with application to vaccine development. Statistics in Medicine 27, 4758-4778.
10. Gustafson, P. and Greenland, S. (2009). Interval estimation for messy observational data. Statistical Science 24, 328-342.
11. Hammer, S. M., Squires, K. E., Hughes, M. D., Grimes, J. M., Demeter, L. M., Currier, J. S., Eron, J. J., Feinberg, J. E., Balfour, H. H., Deyton, L. R., Chodakewitz, J. A., Fischl, M. A., Phair, J. P., Pedneault, L., Nguyen, B., Cook, J. C., and The ACTG 320 Study Team, (1997). A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. New England Journal of Medicine 337, 725-733.
12. Jin, H. and Rubin, D. B. (2008). Principal stratification for causal inference with extended partial compliance. Journal of the American Statistical Association 103, 101-111.
13. Jo, B. and Stuart, E. A. (2009). On the use of propensity scores in principal causal effect estimation. Statistics in Medicine 28, 2857-2875.
14. Li, Y., Taylor, J. M. G., and Elliott, M. R. (2010). A Bayesian approach to surrogacy assessment using principal stratification in clinical trials. Biometrics 66, 523-531.
15. Prentice, R. L. (1989). Surrogate endpoints in clinical trials: Definition and operational criteria. Statistics in Medicine 8, 431-440.
16. Qin, L., Gilbert, P. B., Follmann, D., and Li, D. (2008). Assessing surrogate endpoints in vaccine trials with case-cohort sampling and the cox model. The Annals of Applied Statistics 2, 386-407.
17. Rubin, D. B. (1978). Bayesian inference for causal effects: The role of randomization. The Annals of Statistics 6, 34-58.
18. VanderWeele, T. J. (2011). Principal stratification-Uses and limitations. The International Journal of Biostatistics 7, Article 28.
19. Weir, C. J. and Walley, R. J. (2006). Statistical evaluation of biomarkers as surrogate endpoints: A literature review. Statistics in Medicine 25, 183-203.
20. Wolfson, J. and Gilbert, P. (2010). Statistical identifiability and the surrogate endpoint problem, with application to vaccine trials. Biometrics 66, 1153-1161.